Point72 Asia Singapore Pte. Ltd. Takes $37,000 Position in Pulmonx Co. (NASDAQ:LUNG)

Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Pulmonx Co. (NASDAQ:LUNG) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 5,855 shares of the company’s stock, valued at approximately $37,000.

Other large investors have also modified their holdings of the company. Vanguard Group Inc. grew its position in shares of Pulmonx by 0.6% in the first quarter. Vanguard Group Inc. now owns 2,077,859 shares of the company’s stock valued at $19,262,000 after purchasing an additional 11,417 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in Pulmonx by 7.0% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,059,018 shares of the company’s stock valued at $6,714,000 after buying an additional 69,595 shares during the last quarter. Victory Capital Management Inc. grew its holdings in Pulmonx by 1.0% in the 2nd quarter. Victory Capital Management Inc. now owns 834,301 shares of the company’s stock valued at $5,289,000 after buying an additional 8,004 shares during the last quarter. Renaissance Technologies LLC increased its position in Pulmonx by 13.1% in the 2nd quarter. Renaissance Technologies LLC now owns 301,410 shares of the company’s stock worth $1,911,000 after buying an additional 34,800 shares during the period. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Pulmonx by 12.7% during the second quarter. Bank of New York Mellon Corp now owns 157,902 shares of the company’s stock worth $1,001,000 after buying an additional 17,740 shares during the last quarter. 91.04% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on LUNG shares. Canaccord Genuity Group raised their price objective on shares of Pulmonx from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. Lake Street Capital started coverage on shares of Pulmonx in a research report on Tuesday, June 4th. They issued a “buy” rating and a $12.00 price target on the stock. Finally, Wells Fargo & Company cut their price objective on shares of Pulmonx from $14.00 to $10.00 and set an “equal weight” rating for the company in a research report on Thursday, August 1st. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $14.83.

Pulmonx Price Performance

NASDAQ:LUNG opened at $8.29 on Tuesday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 7.92 and a current ratio of 8.97. The company has a 50-day moving average of $7.26 and a 200-day moving average of $7.58. Pulmonx Co. has a 52 week low of $5.46 and a 52 week high of $14.84. The company has a market capitalization of $321.78 million, a price-to-earnings ratio of -5.38 and a beta of 0.63.

Pulmonx (NASDAQ:LUNG) last released its quarterly earnings data on Wednesday, July 31st. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.02. Pulmonx had a negative return on equity of 50.79% and a negative net margin of 75.56%. The company had revenue of $20.78 million for the quarter, compared to the consensus estimate of $20.23 million. As a group, equities research analysts anticipate that Pulmonx Co. will post -1.64 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Geoffrey Beran Rose sold 4,586 shares of the business’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $6.70, for a total value of $30,726.20. Following the sale, the insider now owns 295,433 shares in the company, valued at approximately $1,979,401.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Pulmonx news, CEO Steven S. Williamson acquired 14,245 shares of the business’s stock in a transaction on Tuesday, August 20th. The stock was purchased at an average price of $6.84 per share, for a total transaction of $97,435.80. Following the transaction, the chief executive officer now owns 219,531 shares in the company, valued at approximately $1,501,592.04. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Geoffrey Beran Rose sold 4,586 shares of the business’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $6.70, for a total value of $30,726.20. Following the completion of the transaction, the insider now directly owns 295,433 shares in the company, valued at approximately $1,979,401.10. The disclosure for this sale can be found here. Insiders sold 30,351 shares of company stock worth $231,094 over the last three months. 5.70% of the stock is currently owned by corporate insiders.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.